Pseudogout flares are triggered when calcium pyrophosphate crystals that have been quietly accumulating in joint cartilage suddenly shed into the surrounding fluid, provoking an intense inflammatory response. The underlying crystal buildup can go on for years without symptoms, so what actually sets off a flare is less about the crystals themselves and more about what disturbs them. Triggers range from surgery and acute illness to metabolic shifts and even rapid changes in blood calcium, and in many cases a clear trigger is never identified at all.
Surgery, Injury, and Physical Stress on the Joint
One of the best-documented triggers for a pseudogout flare is physical disruption of the joint or the body more broadly. Early case-series research identified trauma, surgery, and infection as common antecedents to acute attacks.1PubMed Central. Clinical and roentgenographic aspects of pseudogout: a study of 50 cases and a review The mechanism is straightforward: crystals embedded in cartilage get physically dislodged when the tissue is jostled, compressed, or cut. Once loose in the synovial fluid, they provoke an immediate immune reaction.
Orthopedic surgery is a particularly common culprit. A study of patients undergoing hip fracture surgery found that about 80 percent of those who developed knee effusion afterward had calcium pyrophosphate crystals in their synovial fluid, even though the surgery was on the hip rather than the knee.2PubMed Central. Pseudogout at the knee joint will frequently occur after hip fracture and lead to the knee pain in the early postoperative period That finding is worth pausing on: the flare can show up in a joint that was not operated on at all. The stress of surgery, immobilization, or systemic inflammation appears to be enough to shake crystals loose in a joint that already has deposits. Patients and clinicians sometimes misattribute this post-surgical knee pain to a complication of the hip repair rather than recognizing it as pseudogout, which can delay appropriate treatment.
Direct joint trauma, such as a fall or a sports injury, can have the same effect. Any force that deforms cartilage where crystals are sitting can liberate them into the joint space. Even prolonged immobility followed by sudden movement has been reported to provoke flares, though that trigger is harder to study systematically.
Acute Medical Illness
A pseudogout flare does not always need a local provocation at the joint. Systemic medical events, particularly cardiovascular crises, are a recognized trigger. In a study of hospital patients with pseudogout, more than half of the attacks occurring in medical patients followed an acute vascular event, with flares appearing roughly a week later.3JAMA. Pseudogout Syndrome in Hospital Patients Heart attacks, strokes, and other major vascular episodes seem to create a window of vulnerability. The exact reason is not fully nailed down, but it likely involves a combination of systemic inflammation, shifts in electrolytes and fluid balance, and the metabolic upheaval that comes with critical illness.
This pattern matters for hospital care. When a patient who has been admitted for pneumonia or a cardiac event develops sudden joint swelling and pain a few days later, pseudogout should be on the differential rather than dismissed as a secondary complaint. These hospital-acquired flares are often undertreated because the medical team is focused on the primary diagnosis.
Metabolic Conditions That Promote Crystal Buildup
Some people are far more prone to pseudogout because of underlying metabolic disorders that change the chemistry of their joints. The most well-established of these is hyperparathyroidism. When the parathyroid glands overproduce parathyroid hormone, calcium levels in the blood rise, and that excess calcium promotes the deposition of calcium pyrophosphate crystals in cartilage. In a series of 20 patients with pseudogout, eight had intermittent arthritic attacks that ultimately led to a confirmed diagnosis of primary hyperparathyroidism, suggesting pseudogout can serve as an early clinical clue to the condition.4PubMed. Pseudogout as a clue and complication in primary hyperparathyroidism
Hemochromatosis, a condition of excess iron storage, is another recognized predisposing factor. Iron overload appears to interfere with bone and cartilage metabolism in ways that favor crystal formation. The connection between iron and pseudogout was initially noticed because patients with hemochromatosis had unusually high rates of chondrocalcinosis, the visible calcification of cartilage on X-rays. Lab work suggests that elevated iron levels increase the activity of cells involved in bone resorption, which may alter the local mineral environment in joints and promote crystal deposition.5ACR Meeting Abstracts. Hemochromatosis Is Associated with CPPD Through Iron’s Effect on Bone
Low magnesium levels are a third metabolic culprit. Magnesium normally helps dissolve pyrophosphate, so when magnesium drops, pyrophosphate can accumulate more easily and crystallize. This link is particularly relevant in younger patients who develop pseudogout, since the disease is overwhelmingly associated with aging and early-onset cases raise suspicion for an underlying metabolic driver.6PubMed Central. Magnesium disorders can cause calcium pyrophosphate deposition disease: A case report and literature review Chronic use of proton-pump inhibitors, alcoholism, and certain kidney conditions can all deplete magnesium over time.
Chronic kidney disease deserves separate mention. A population-level study found that chronic renal failure roughly doubled the odds of pseudogout, making it one of the few clearly supported independent risk factors.7PubMed Central. Risk factors for pseudogout in the general population Impaired kidneys struggle to clear phosphate and maintain mineral balance, creating conditions that favor crystal formation.
When Calcium Levels Shift Suddenly
The relationship between calcium and pseudogout is not just about chronically high levels. Some of the most dramatic flares happen when calcium drops quickly. Patients with hyperparathyroidism who undergo parathyroidectomy, the surgical removal of the overactive gland, can experience a sudden correction in blood calcium. That rapid downward shift appears to destabilize crystals already embedded in cartilage, causing them to shed into the joint fluid and triggering an acute attack.8PubMed. Acute pseudogout following parathyroidectomy The phenomenon is sometimes described as a paradox: the surgery cures the metabolic problem but temporarily worsens the joint disease.
This is not limited to parathyroid surgery. Any situation that causes a rapid swing in calcium, such as aggressive intravenous fluid resuscitation, bisphosphonate therapy, or correction of vitamin D deficiency, could theoretically provoke a similar crystal-shedding event in someone with pre-existing deposits. The clinical take-home is that people known to have chondrocalcinosis should be monitored for joint symptoms when their calcium levels are being actively corrected.
What Happens Inside the Joint During a Flare
Once crystals land in the synovial fluid, the immune system treats them like foreign invaders. Macrophages, a type of white blood cell, engulf the crystals and activate a specific inflammatory pathway driven by a protein complex called NLRP3. This leads to the release of interleukin-1β, a potent inflammatory signaling molecule that recruits neutrophils and amplifies the swelling, redness, and pain characteristic of a flare.
Research has shown that this entire cascade depends heavily on glucose metabolism within the macrophages. When crystals activate macrophages, the cells ramp up glucose uptake through a transporter called GLUT1 and shift into a high-energy mode. Blocking glucose uptake or inhibiting this metabolic shift in lab settings suppressed the inflammatory response, including the formation of the NLRP3 complex and the production of interleukin-1β.9Annals of the Rheumatic Diseases. Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1β activation on macrophages This glucose-dependence is shared with gout, where urate crystals trigger an almost identical inflammatory pathway. It also suggests that the metabolic state of the body at the time crystals are shed may influence how severe the resulting flare becomes.
Interestingly, the same crystals that provoke explosive inflammation in one person can sit quietly in another person’s joints for decades without ever causing symptoms. Why the immune system tolerates the crystals in some cases and attacks them in others is still an open question, and it is one of the reasons pseudogout remains harder to predict and prevent than gout.
Genetic Predisposition
Most pseudogout occurs sporadically in older adults, but familial forms exist and shed light on why some people accumulate crystals far more readily than others. Mutations in the ANKH gene, which encodes a protein involved in transporting pyrophosphate out of cells, have been identified in families with early-onset chondrocalcinosis.10PubMed Central. Mutations in ANKH cause chondrocalcinosis These mutations increase the activity of the ANKH protein, resulting in higher concentrations of pyrophosphate outside cells, which promotes crystal formation in cartilage.11PubMed. The ANKH gene and familial calcium pyrophosphate dihydrate deposition disease
In affected families, pseudogout appears much earlier in life, sometimes in the 30s or 40s, compared to the typical onset after age 60. The disease also tends to be more aggressive, involving more joints and causing more structural damage over time. If you develop pseudogout before age 55 and have relatives with joint problems, genetic testing for ANKH mutations may be worth discussing with a rheumatologist. For the far more common sporadic cases in older adults, though, genetic factors are less clearly defined and routine genetic testing is not part of standard care.
How Pseudogout Flares Differ from Gout
The two crystal-related arthritis conditions share surface-level similarities, enough that distinguishing them clinically can be tricky. Both cause sudden, severe joint pain and swelling. But the details diverge in useful ways. Pseudogout tends to strike older patients (average age around 79 in one cross-sectional study, compared with about 67 for gout) and favors the knee, wrist, and ankle, whereas gout classically hits the base of the big toe.12PubMed. An investigation of the independent risk factors that differentiate gout from pseudogout in patients with crystal-induced acute arthritis: a cross-sectional study Pseudogout attacks were more likely to involve a single joint with prominent soft-tissue swelling around the joint, while gout was more associated with a history of recurrent attacks and elevated uric acid levels.
The distinction matters because the triggers are different. Gout flares are strongly associated with diet, alcohol, and uric acid metabolism, so dietary changes and urate-lowering medications are central to prevention. Pseudogout has no equivalent dietary lever. The same population-level study that identified chronic kidney disease as a risk factor for pseudogout found that BMI, thiazide diuretic use, and other traditional gout risk factors were not associated with pseudogout at all.7PubMed Central. Risk factors for pseudogout in the general population If you have been diagnosed with pseudogout and are trying to manage flares through the same dietary restrictions commonly advised for gout, you are likely making unnecessary sacrifices for no measurable benefit.
How a Flare Is Diagnosed
Confirming pseudogout during a flare requires looking at the joint fluid under a microscope. A needle is inserted into the swollen joint to withdraw synovial fluid, which is then examined under polarized light. Calcium pyrophosphate crystals are weakly birefringent and appear as rhomboid or rod-shaped particles, in contrast to the needle-shaped, strongly birefringent crystals of gout.13Pseudogout: Uncommon and Under-Recognized. Pseudogout: Uncommon and Under-Recognized This crystal analysis is the definitive diagnostic step. Imaging can support the diagnosis, particularly X-rays showing chondrocalcinosis in cartilage, but the presence of calcification on imaging does not necessarily mean the person is having an active flare. Many people have cartilage calcification without ever experiencing symptoms.
Blood tests play a supporting role. They can help identify an underlying metabolic driver such as hyperparathyroidism, hemochromatosis, or low magnesium, but they cannot confirm or rule out a pseudogout flare on their own. If you are having recurrent flares, checking calcium, parathyroid hormone, iron studies, and magnesium is reasonable to rule out treatable conditions that could be feeding the crystal formation.
Treating an Acute Flare
There is no medication that dissolves calcium pyrophosphate crystals or prevents them from forming, which is the fundamental frustration of managing pseudogout. Treatment focuses entirely on controlling the inflammation once a flare strikes. The standard first-line options are nonsteroidal anti-inflammatory drugs, corticosteroids (injected directly into the joint or taken by mouth for a short course), and colchicine.14PubMed Central. Anakinra for Refractory Pseudogout in Patients with End-stage Renal Disease on Haemodialysis Each has limitations. Anti-inflammatories can be hard on the kidneys and stomach, especially in the older population most affected by pseudogout. Corticosteroids carry their own risks with repeated use. Colchicine can cause gastrointestinal side effects and needs dose adjustment in people with kidney problems.
For patients who cannot tolerate any of the standard options, particularly those with advanced kidney disease, biologic agents that target interleukin-1β directly have shown promise. Anakinra, an interleukin-1 receptor antagonist, has been used successfully in refractory cases, resolving acute attacks and maintaining remission while allowing patients to stop corticosteroids entirely.14PubMed Central. Anakinra for Refractory Pseudogout in Patients with End-stage Renal Disease on Haemodialysis It remains an off-label option and is not widely used, but it fills a real gap for patients who have run out of conventional choices.
Low-dose colchicine taken daily is sometimes used as prophylaxis in people with frequent flares, though evidence for this approach is borrowed more from gout management than from dedicated pseudogout trials. The honest state of pseudogout therapeutics is that prevention is much harder than in gout, where lowering uric acid addresses the root cause. Without an equivalent metabolic target, managing pseudogout is largely reactive.
Why Some Flares Have No Obvious Trigger
For all the identifiable triggers discussed above, a large fraction of pseudogout flares arrive without any clear provocation. The patient has not had surgery, is not acutely ill, and has stable metabolic parameters. These idiopathic flares are frustrating because they resist the logic of avoidance. You cannot dodge a trigger you cannot name.
Part of the explanation may be mechanical. Cartilage is a living tissue that undergoes constant low-level turnover, especially in aging joints affected by osteoarthritis. Routine wear and micro-damage could periodically dislodge crystals without any dramatic event. Temperature changes, fluctuations in joint fluid volume, and even the mild dehydration that comes with a poor night’s sleep have been proposed as contributing factors, though none of these has strong evidence behind it.
The variability in immune tolerance also plays a role. As noted earlier, crystals can sit in joints for years without symptoms. What changes the immune system’s posture toward those crystals on any given day is poorly understood. Some researchers suspect that low-grade infections, shifts in circulating cytokines, or changes in the protein coating on crystal surfaces can flip the immune response from tolerant to aggressive. The research here is still early, and it represents one of the more frustrating frontiers in rheumatology: we can describe what happens during a flare in considerable molecular detail, but we still cannot reliably predict when one will start.